Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab

BACKGROUND: To evaluate the association between immune-related adverse events (irAEs) and the clinical outcomes and also between irAEs and the post-treatment changes in the relative eosinophil count (REC) in advanced urothelial carcinoma (UC) patients treated with pembrolizumab. MATERIALS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Furubayashi, Nobuki, Minato, Akinori, Negishi, Takahito, Sakamoto, Naotaka, Song, Yoohyun, Hori, Yoshifumi, Tomoda, Toshihisa, Harada, Mirii, Tamura, Shingo, Miura, Akihiro, Komori, Hiroki, Kuroiwa, Kentaro, Seki, Narihito, Fujimoto, Naohiro, Nakamura, Motonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078345/
https://www.ncbi.nlm.nih.gov/pubmed/35535266
http://dx.doi.org/10.2147/CMAR.S360473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078345/
https://www.ncbi.nlm.nih.gov/pubmed/35535266
http://dx.doi.org/10.2147/CMAR.S360473

Ejemplares similares